

SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878
Revision date: 02/11/2022
Version number: 04

1. Identification of the substance or preparation and the company/ undertaking

1.1 Product Identifier

Product Name: Mast Yersinia Selectatab™

Product Code: MS19 series

1.2 Relevant identified uses of the substance or mixture and uses advised against

Recommended uses: *In vitro* diagnostic product; Laboratory chemical

Uses advised against: No information available

1.3 Details of supplier of the product and safety data sheet

Manufacturer/supplier: Mast Group Ltd., Mast House,
Derby Road,
Bootle,
Merseyside,
UK.
L20 1EA
Telephone: +44 (0) 151 933 7277
Email: uksales@mastgrp.com
Web: www.mastgrp.com

Feldstraße 20
23858 Reinfeld
Germany
Telephone: +49 4533 20 07 34
Email: mast@mast-diagnostics.de
Web: www.mast-group.com

1.4 Emergency Contact information

UK contact: Telephone: +44 (0) 151 933 7277 (8am - 5pm GMT Monday to Friday)

EU contact: Telephone: +49 4533 20 07 34 (7am - 4pm GMT Monday to Friday)

2. Hazards identification

2.1 Classification of the substance or mixture

CLP Classification – Regulation (EC) No. 1272/2008:

Physical hazards: Based on available data, there are no physical hazards

Health hazards: Skin Irritant Cat. 2; Eye Irritant Cat. 2; Skin Sensitization Cat. 1.

Environmental hazards: Based on available data, there are no environmental hazards

2.2 Label elements

Pictogram:



Signal word: Warning

Hazard statements: H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H319 - Causes serious eye damage.

Precautionary statements: P280 Wear protective gloves.
P342 + P311 If experiencing respiratory symptoms: Call a poison centre or doctor/
physician.

2.3 Other hazards

No information available

SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878
Revision date: 02/11/2022
Version number: 04

3. Composition/information on ingredients

Composition: A multi-component freeze-dried tablet containing irgasan, cefsulodin and novobiocin in an inert carrier.

Hazardous ingredients:

Component	CAS-No.	EC-No.	Concentration	CLP Classification – 1272/2008/EC	Classification to – 67 /548/EEC
Irgasan/ Triclosan	3380-34-5	224-182-2	2.2%	Skin Irritation Cat. 2; Eye Irritation Cat. 2; Acute aquatic toxicity Cat. 1; Chronic aquatic toxicity Cat. 1; H315 - Causes skin irritation. H319 - Causes serious eye damage. H410 - Very toxic to aquatic life with long lasting effects.	Xn - Harmful. N - Dangerous for the environment. R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R36/38 - Irritating to eyes and skin.
Cefsulodin	52152-93-9	257-692-4	8.7%	Skin Irritation Cat. 2; Eye Irritation Cat. 2; Skin sensitisation Cat. 1; Specific target organ toxicity - single exposure Cat. 3. H315 - Causes skin irritation. H317 - May cause an allergic skin reaction H319 - Causes serious eye damage. H335 - May cause respiratory irritation	Xi - Irritant. Xn - Harmful. R36/37/38 - Irritating to eyes, respiratory system and skin. R42/43 - May cause sensitization by inhalation and skin contact.
Novobiocin	1476-53-5	216-023-6	1.5%	Eye irritation Cat. 2; Skin Sensitization Cat. 1; H317 - May cause an allergic skin reaction H319 - Causes serious eye damage.	Xi - Irritant. R36 - Irritating to eyes. R43 - May cause sensitization by skin contact.

4. First-aid measures

4.1 Description of First Aid measures

General advice: Consult a physician. Show this safety data sheet to the doctor in attendance.

Eye contact: Rinse thoroughly with plenty of water for 10 to 15 minutes, also under the eyelids. Obtain medical attention if irritation persists.

Skin Contact: Wash off skin thoroughly with soap and plenty of water. Obtain medical attention if irritation persists.

Ingestion: Rinse mouth out with plenty of water. Obtain medical attention if symptoms occur.

Inhalation: Move person to fresh air. Obtain medical attention immediately if symptoms occur.

4.2 Most important symptoms and effects, both acute and delayed

No information available.

4.3 Indicate any immediate medical attention and special treatment needed

No information available.

5. Fire fighting measures

5.1 Extinguishing medium

Suitable extinguishing media: Use water spray, CO₂, foam or dry powder as the extinguisher medium.

Extinguishing media which must not be used for safety reasons: No information available

5.2 Special hazards arising from the substance or mixture

Combustible material. Thermal decomposition may lead to release of irritating gases and vapours.

5.3 Advice for firefighters

Wear suitable self contained breathing apparatus for fire fighting if necessary.

5.4 Additional information

No data available.

SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878
Revision date: 02/11/2022
Version number: 04

6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Wear appropriate protective equipment. Avoid dust formation.

6.2 Environmental precautions

Should not be released into the environment.

6.3 Methods and materials for contamination and cleaning up

Sweep up or vacuum up spillage in suitable container for disposal. Avoid dust formation.

6.4 Further information

No data available.

7. Handling and storage

7.1 Precautions for safe handling

Avoid contact with eyes, skin and clothing. Avoid ingestion and inhalation. Avoid dust formation.

7.2 Conditions for safe storage, including any incompatibilities

Store at 2 to 8°C. Keep tightly closed in the container provided. Protect from direct sunlight and moisture.

7.3 Specific end use(s)

This product is for laboratory use only and should only be used by suitably trained laboratory personnel.

8. Exposure controls and personal protection

8.1 Control parameters

Components with workspace control parameters: Contains no substance with occupational exposure limits.

8.2 Exposure controls

Engineering controls: No engineering protection required.

Personal protective measures: Body protection: Wear standard microbiology laboratory coat.

Eye/face protection: Safety glasses with side shields conforming to EN 166.

Skin and hand protection: Handle with suitable gloves conforming to EN 374.

Respiratory protection: Wear a face mask to EN149 FFP2S or use a ventilated extraction weighing cabinet.

General hygiene measures: Handle in accordance with good laboratory practice.
Wash hands before breaks and at the end of the working day.

SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878
Revision date: 02/11/2022
Version number: 04

9. Physical and Chemical properties

9.1 Information on basic physical and chemical properties

Physical appearance:	Lyophilised tablet.
Colour:	White to off-white colour.
Odour:	No detectable odour.
Odour threshold:	No data available.
Melting point/freezing point:	No data available.
Initial boiling point/range	No data available.
Flammability (solid, gas):	No data available.
Explosive limits:	No data available.
Flash point:	No data available.
Auto-ignition temperature:	No data available.
Decomposition temperature:	No data available.
pH value:	No data available.
Partition coefficient (n-octanol/water):	No data available.
	No data available.
Vapour pressure:	No data available.
Vapour density:	No data available.
Relative density:	No data available.
Solubility in water:	Soluble to partially soluble in water.
Solubility in other solvents:	No data available.
Viscosity:	No data available.
Vapour density:	No data available.
Explosive properties	This product is not explosive in normal circumstances.
Oxidising properties:	No data available.
Evaporation rate:	

9.2 Other information

No data available.

10. Stability and reactivity

10.1 Reactivity

No known on information available.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

No data available.

10.4 Conditions to avoid

Hygroscopic. Avoid exposure to sunlight.

10.5 Incompatible materials

None known.

10.6 Hazardous decomposition products

None under normal use conditions.

SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878
Revision date: 02/11/2022
Version number: 04

11. Toxicological information

11.1 Information on toxicological effects

Overall product information: This product does not present an acute toxicity based on known or supplied information.

Acute toxicity: For Irgasan: LD₅₀ Oral - rat - 3,700 mg/kg; LD₅₀ Dermal - rabbit - 9,300 mg/kg.
For further information see RTECS: KO1100000

For cefsulodin: LD₅₀ Oral - rat - > 15,000 mg/kg. For further information see RTECS: UU1785000

For novobiocin: LD₅₀ Oral - rat - 3,500 mg/kg. For further information see RTECS: RD5425000

Skin corrosion/irritation: No data available.

Serious eye damage/ eye irritation: No data available.

Respiratory or skin sensitisation: May cause allergic respiratory and skin reactions.

Germ cell mutagenicity: No data available.

Carcinogenicity: No data available.

Reproductive toxicity: No data available.

Specific target organ toxicity – single exposure: No data available.

Specific target organ toxicity – repeated exposure: No data available.

Aspiration hazard: No data available.

Potential health effects: Inhalation - May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion - May be harmful if swallowed.
Skin - May be harmful if absorbed through skin. May cause skin irritation.
Eyes - May cause eye irritation.

11.2 Toxicological data for the components

Assess endocrine disrupting properties for human health. This product does not contain any known or suspected endocrine disruptors.

12. Ecological information

12.1 Toxicity

For Irgasan:

Toxicity to fish LC₅₀ - *Oncorhynchus mykiss* (rainbow trout) - 0.288 mg/l - 96.0 h

Toxicity to daphnia and other aquatic invertebrates EC₅₀ - *Daphnia magna* (Water flea) - 0.39 mg/l - 48 h

12.2 Persistence and degradability

Expected to be biodegradable.

12.3 Bioaccumulative potential

No data available.

12.4 Mobility in soil

No data available.

12.5 Results of PBT and vPvB assessment

This substance/mixture contains no components considered to be persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects.

No data available.

SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878
Revision date: 02/11/2022
Version number: 04

13. Disposal considerations

Disposal considerations: Dispose of in accordance with local and national regulations.
Dispose of all used contaminated waste, e.g. used plates, according to local microbiological rules.

14. Transport information

14.1 UN Number

ADR/RID: IMDG: IATA: Not dangerous for shipping

14.2 UN proper shipping name

ADR/RID: IMDG: IATA: Not dangerous for shipping

14.3 Transport hazard class(es)

ADR/RID: IMDG: IATA: Not dangerous for shipping

14.4 Packaging group

ADR/RID: IMDG: IATA: Not dangerous for shipping

14.5 Environmental hazards

ADR/RID: IMDG: IATA: None known.

14.6 Special precautions for user

No data available

15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

No data available.

15.2 Chemical safety assessment

Chemical safety assessment reports are not required for mixtures/IVD products.

16. Other information

Original origination date: 22/05/1996

Reason for change to document: Updated in accordance with Regulation (EC) No 2020/878

The above information is believed to be correct but does not purport to be all inclusive and shall be used as a guide only. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product and is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. Mast Group Ltd. shall not be held liable for any damage resulting from handling or from contact with the above product. See our website at www.mast.grp.com and/or the reverse side of our invoice for additional terms and conditions of sale.